A61K 2239/57
Skin
Official title: Skin; melanoma
A61K2239/57 (Skin) appears on 461 US grants and 1,014 published applications in this corpus.
Search patents in A61K- Granted patents
- 461
- Published applications
- 1,014
- Assignees
- 480
- Inventors
- 1,816
- Latest grant
- 29 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1996 | 1 | 0 |
| 1997 | 1 | 0 |
| 1998 | 5 | 0 |
| 1999 | 2 | 0 |
| 2000 | 6 | 0 |
| 2001 | 2 | 1 |
| 2002 | 2 | 9 |
| 2003 | 2 | 7 |
| 2004 | 3 | 11 |
| 2005 | 2 | 12 |
| 2006 | 5 | 16 |
| 2007 | 0 | 11 |
| 2008 | 4 | 14 |
| 2009 | 3 | 24 |
| 2010 | 9 | 24 |
| 2011 | 13 | 19 |
| 2012 | 10 | 17 |
| 2013 | 19 | 19 |
| 2014 | 11 | 30 |
| 2015 | 10 | 21 |
| 2016 | 21 | 25 |
| 2017 | 22 | 47 |
| 2018 | 16 | 40 |
| 2019 | 15 | 66 |
| 2020 | 26 | 74 |
| 2021 | 38 | 89 |
| 2022 | 46 | 121 |
| 2023 | 38 | 100 |
| 2024 | 45 | 101 |
| 2025 | 47 | 66 |
| 2026 | 37 | 50 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Modulation of expression of genes related to T cell exhaustion29 Sep 2026US 12,747,431 B2The Trustees of the University of Pennsylvania
- Immune cells with enhanced cytotoxicity and methods of use thereof29 Sep 2026US 12,747,443 B2Ludwig Institute for Cancer Research
- Cell capable of activating immune system, and pharmaceutical composition containing said cell11 Aug 2026US 12,703,867 B2Riken
- Compositions and methods regarding engineered and non-engineered γδ T-cells for treatment of solid tumors4 Aug 2026US 12,698,340 B2Adicet Therapeutics, Inc.
- Peptide markers to track genetically engineered cells21 Jul 2026US 12,686,708 B2Neogene Therapeutics B.V.
- Plasmacytoid dendritic cells for treating cancer17 Sep 2026US 2026/0272977 A1Pdc Line Pharma
- Anti-new york esophageal squamous cell carcinoma 1 (ny-eso-1) antigen-binding proteins and methods of use thereof17 Sep 2026US 2026/0274962 A1Regeneron Pharmaceuticals, Inc.
- Restimulation of cryopreserved tumor infiltrating lymphocytes17 Sep 2026US 2026/0275285 A1Iovance Biotherapeutics, Inc.
- Restimulation of cryopreserved tumor infiltrating lymphocytes17 Sep 2026US 2026/0275286 A1Iovance Biotherapeutics, Inc.
- Il-9r signaling compositions and methods10 Sep 2026US 2026/0263516 A1The Regents of the University of California
Most cited
By later US patents
- Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy258US 8,034,334 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2011
- Adoptive cell therapy with young T cells191US 8,383,099 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2013
- Alternative open reading frame DNA of a normal gene and a novel human cancer antigen encoded therein139US 5,840,839 AThe United States of America, as represented by the Secretary, Department of Health and Human Services · 1998
- Adoptive cell therapy with young T cells137US 9,074,185 B2The United States of America, as represented by the Secretary, Department of Health and Human Services · 2015
- Human application of engineered chimeric antigen receptor (CAR) T-cells110US 9,629,877 B2Board of Regents, The University of Texas System · 2017